BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Post-Approval (World)
Roche (RHHBY), Merck & Co. (MRK) Extend Immunotherapy Battle To Breast Cancer 10/17/2014
Celgene International Sárl (CELG) Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis 10/10/2014
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis 10/10/2014
Celgene International Sárl (CELG) To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress 10/7/2014
Daiichi Sankyo, Inc. (4568.t) Receives Approval For Additional Indications Of LIXIANA® (Edoxaban) In Japan 9/26/2014
Regeneron Pharmaceuticals, Inc. (REGN) Announces EYLEA® (aflibercept) Injection Approved For The Treatment Of Patients With Myopic Choroidal Neovascularization (CNV) In Japan 9/22/2014
Janssen-Cilag International NV (JNJ) Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes 9/17/2014
Study Shows Novo Nordisk A/S (NVO)'s New Diabetes Drug Tresiba Effective And Safe For Children 9/16/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents New Data Which Demonstrate Reduction Of Injection-Related Adverse Events With The Less Frequent Dosing Of Three-Times-A-Week COPAXONE® (Glatiramer Acetate Injection) 40 Mg Compared To Daily COPAXONE® 20 Mg 9/11/2014
Novartis AG (NVS): Rate Of Brain Shrinkage Faster In Multiple Schlerosis Patients 9/10/2014
Novaliq GmbH Announces Positive Results From Novatears® Observational Study In Mild To Moderate Evaporative Dry Eye Disease 9/10/2014
Amgen (AMGN), Servier Heart Drug Runs Into Safety Concerns In Major Clinical Study 9/4/2014
Vifor Pharma Release: CONFIRM-HF Study Demonstrates That Injectafer® (Ferinject®) Improves Exercise Capacity In Patients With Chronic Heart Failure 9/2/2014
Boehringer Ingelheim Corporation Release: European Society of Cardiology Congress 2014 Hot Line Session: Favourable Effect Of Pradaxa® On Kidney Function Over Time Compared To Warfarin 9/2/2014
Sanofi Pasteur (SASY.PA) Touts Positive Trial Data For Fluzone High-Dose Vaccine 8/14/2014
Scientists Retract Narcolepsy Study Linked To GlaxoSmithKline (GSK) Flu Vaccine 8/11/2014
Study Claims Celgene (CELG) Drug Can Drive HIV Out Of Hiding 7/25/2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands 7/21/2014
Shire Reports Results From Two Head-To-Head Studies Comparing Vyvanse® With Concerta® In ADHD Study 7/18/2014
Merck & Co., Inc. (MRK)'s Gardasil HPV Vaccine Doesn't Increase Blood Clot Risk 7/9/2014
Roche (RHHBY) Finds "Serious Flaws" In Recent Study Doubting Tamiflu's Effectiveness 7/1/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression 6/26/2014
A 4-Week Hepatitis C Cure? Bristol-Myers Squibb Company (BMY) To Test Drugs With Gilead Sciences, Inc. (GILD)'s Sovaldi 6/23/2014
H. Lundbeck A/S (LUN.CO) Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Results Of A New Study Of Brintellix® (vortioxetine) vs. Escitalopram On Sexual Functioning In Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Shows That Brintellix® (Vortioxetine) Improves Cognitive Performance And Function In Adult Patients With Major Depression 6/16/2014
Hemispherx Biopharma (HEB) Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS) 6/16/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Boehringer Ingelheim Corporation Release: Antidote For Rapid Reversal Of Pradaxa® (Dabigatran Etexilate) Progresses Into Next Stage Of Clinical Investigation With Study In Patients 5/22/2014
GlaxoSmithKline (GSK) Touts Positive Incruse™-Ellipta®-Advair®-Diskus® Combo Data 5/20/2014
Biohit Release: Enrollment To Clinical Trials For Prevention Of Migraine-Type Headache 5/19/2014
Biohit Starts Two Clinical Trials With Acetium® Capsule For Prevention Of Migraine-Type Headache 4/29/2014
Head-To-Head Study Reveals Novartis AG (NVS) Lung Drug Not Inferior To GlaxoSmithKline (GSK)'s Seretide 4/28/2014
Saga Continues: Roche (RHHBY)'s Tamiflu No Better Than Tylenol At "Fighting Flu" 4/14/2014
FDA Grants Breakthrough Status Designation To Novartis AG (NVS)' Meningitis B Vaccine 4/8/2014
H. Lundbeck A/S (LUN.CO) Release: Treatment With Once-Monthly Abilify Maintena® (Aripiprazole) Significantly Reduces Hospitalisation Rates For Patients With Schizophrenia Compared With Daily Oral Antipsychotics 4/7/2014
Roche (RHHBY)-Backed Study Finds Tamiflu Saved Lives In Flu Pandemic 3/19/2014
uniQure And Chiesi Farmaceutici SpA Announce Six Year Follow-up Data from Glybera® Treated Patients 3/17/2014
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014
Baxter International, Inc. (BAX) Presents Data At EAHAD From Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience With ADVATE 2/27/2014
Roche (RHHBY) May Share Avastin Brain Cancer Data Amid Conflicting Results 2/21/2014
Ranbaxy Laboratories (RANBAXY.BO) Workers Fudged Test Results: FDA 1/28/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE® (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate 1/13/2014
German Watchdog Deals Setback To Bayer AG (BAYN.DE) Eye Drug Eylea 1/6/2014
AstraZeneca PLC (AZN)'s Arimidex Halves Breast Cancer Risk, Study Finds 12/12/2013
Lundbeck Inc. (LUN.CO) Release: New Study Showed Improvement In Cognitive Performance In Adult Patients Treated With Brintellix® (Vortioxetine) For Acute Episodes Of Major Depression 12/11/2013
Zealand Pharma  (ZEAL.CO) Informs That New Data Presented At The World Diabetes Congress Support Flexibility In Timing Of Administration For Lyxumia® 12/5/2013
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/2/2013
Boehringer Ingelheim Corporation Release: Pradaxa® (Dabigatran Etexilate) 150mg Bid Continues To Be The Only Oral Anticoagulant Which Showed Superior Ischaemic Stroke Reduction Vs. Warfarin In Its Pivotal Study RE-LY® 11/25/2013
Boehringer Ingelheim Corporation Planning Two New Global Clinical Trials For Pradaxa® (Dabigatran Etexilate) In Expanded Patient Populations 11/19/2013
First Human Data Show Promise Of Boehringer Ingelheim Corporation’s Specific Antidote For Immediate, Complete And Sustained Reversal Of Pradaxa®-Induced Anticoagulation 11/18/2013
EU Agency Questions AstraZeneca PLC (AZN) Over Heart Drug Trial 11/8/2013
Ibuprofen No Good in Treating Colds or Sore Throats, University of Southampton Study 11/5/2013
Roche (RHHBY)'s Avastin Boosts Survival in Advanced Ovarian Cancer 10/23/2013
Novo Nordisk A/S (NVO) Study Shows Tresiba Efficacy for Diabetes 9/26/2013
Data Show Sanofi (France) (SAN.PA)'s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially When Fasting Plasma Glucose Was Controlled 9/24/2013
Roche (RHHBY)'s Perjeta Works in Early-Stage Breast Cancer 9/11/2013
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study 9/3/2013
FDA Probes Brain Infection in Patient on Novartis AG (NVS)'s MS Drug 9/3/2013
Novartis AG (NVS)'s Afinitor® Fails Phase 3 Liver Cancer Trial 8/8/2013
Orexo AB: First Patient Dosed in New Study on Long-Term Adherence to Treatment of Opioid Dependence With Zubsolv® 8/7/2013
Deja Vu: Second Probe Finds Manipulated Trial Data for Novartis AG (NVS) Drug 8/5/2013
Celgene International Sárl (CELG) Release: Study of REVLIMID® (lenalidomide) in Patients with High-Risk Asymptomatic Smoldering Multiple Myeloma Published in The New England Journal of Medicine 8/1/2013
European Medicines Agency Approves SmPC Change to Baxter International, Inc. (BAX)’s ADVATE to Include Information on PK-Guided Dosing Study 7/22/2013
Roche (RHHBY)'s Avastin as Good as Novartis AG (NVS)'s Lucentis for AMD 7/19/2013
Boehringer Ingelheim Corporation Release: Benefits of Pradaxa® Maintained in Difficult to Treat Patients With Atrial Fibrillation and Symptomatic Heart Failure 7/16/2013
Novartis AG (NVS) Drug Study Data Manipulated: Kyoto Prefectrual University of Medicine 7/16/2013
Baxter International, Inc. (BAX) Presents ADVATE Data on Prophylaxis Management and Efficacy for Hemophilia A Patients 7/8/2013
Boehringer Ingelheim Corporation Release: New Long-Term Data Reinforce Safety Profile of Pradaxa® for Stroke Prevention in AF 6/17/2013
Celgene International Sárl (CELG) Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients With Rare Form of Blood Disease 6/17/2013
Novo Nordisk A/S (NVO) Release: Victoza® (Liraglutide [rDNA Origin] Injection) Safety Profile Further Supported at Scientific Workshop on Pancreatitis, Diabetes and Pancreatic Cancer 6/14/2013
AbbVie (ABBV) Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination With HUMIRA™ (adalimumab) for Rheumatoid Arthritis 6/13/2013
Bristol-Myers Squibb Company (BMY)'s Orencia Matches Abbott Laboratories (ABT)' Humira in Arthritis Study 6/12/2013
Merck & Co., Inc. (MRK) Joins Novo Nordisk A/S (NVO) to Reassure Safety of Diabetes Drugs 6/12/2013
Sanofi (France) (SAN.PA) Steps Up Diabetes Drive as Rivals Raise the Stakes 6/10/2013
Eisai Company, Ltd. (ESALY.PK) Confirms Therapeutic Effects of Lenvatinib in Patients With Melanoma in Strategic Collaboration With Quintiles, Inc. (Q) to Develop Eisai Anticancer Compounds 6/10/2013
New Bird Flu Found to be Resistant to Roche (RHHBY)'s Tamiflu 5/30/2013
Boehringer Ingelheim Corporation Release: New European Survey Highlights Ischaemic Stroke Protection as Treatment Priority for Patients With Atrial Fibrillation 5/28/2013
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO): Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1 5/21/2013
"Love Hormone" Promises Safer Births After Pfizer Inc. (PFE) Flop 5/21/2013
Teva Pharmaceutical Industries Limited (TEVA) Parkinson's Treatment Meets Study Goals 3/20/2013
German Cost Regulator Rejects Bayer AG (BAY.F) and Regeneron Pharmaceuticals, Inc. (REGN) Eye Drug 3/20/2013
EU Expands Use of Roche (RHHBY)'s Pegasys in Chronic Hepatitis C 3/18/2013
Ferring Pharmaceuticals Data Suggest Lower Risk of Cardiovascular Events or Deaths in Prostate Cancer Patients Treated With Degarelix Compared to LHRH Agonists 3/18/2013
AbbVie (ABBV) Seeks to Block Release of Clinical Trial Data 3/11/2013
Serious Side Effects Seen With Failed Merck & Co., Inc. (MRK) Niacin Drug 3/11/2013
Roche (RHHBY)'s Rituxan Cures Rare Skin-Blistering Disease in Study 3/8/2013
National Institute for Clinical Excellence (NICE) U-Turn on Novartis AG (NVS)'s Xolair for Asthma 3/7/2013
Boehringer Ingelheim Corporation Release: New Findings From Two Studies Support Substantial Benefit of Pradaxa® for Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism 2/21/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix 1/24/2013
Novartis AG (NVS) Says Afinitor Reduces Tumors in Rare Genetic Disease 1/11/2013
Merck & Co., Inc. (MRK)'s Tredaptive is Under Review by European Medicines Agency After Failed Trial 12/26/2012
Immune Response BioPharma Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS 12/13/2012
Novo Nordisk A/S (NVO) Bets on Turning Victoza Into Obesity Blockbuster 12/12/2012
Celgene International Sárl (CELG) Release: Analysis of Post-Progression Outcomes in MM-015 Study Presented at the 54th American Society of Hematology Annual Meeting 12/11/2012
Genentech (RHHBY)'s Perjeta Extends Life of Breast Cancer Patients by 34 Pct 12/11/2012
Celgene (CELG) Release: REVLIMID® and VIDAZA® Combination Therapy Achieves Nearly 30 Percent Complete Response in Untreated Elderly Patients With Acute Myeloid Leukemia 12/11/2012
Boehringer Ingelheim Corporation Release: Treatment With Pradaxa® Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin 12/10/2012
GlaxoSmithKline (GSK): We Conducted Paxil Clinical Trial Program Appropriately 12/7/2012
AstraZeneca PLC (AZN) Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2 12/5/2012
Eli Lilly and Company (LLY)'s ED Drug, Cialis, Shows Promise in Rare Muscle Disease 11/30/2012
Digoxin for Atrial Fibrillation Questioned After Deaths, Study Published in the European Heart Journal 11/28/2012
Novo Nordisk A/S (NVO) Says New Data Show Victoza Advantage 11/27/2012
Roche (RHHBY)'s Avastin Shows Mixed Results in Glioblastoma 11/23/2012
Gilead Sciences, Inc. (GILD)'s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients 11/15/2012
Gilead Sciences, Inc. (GILD)'s Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naive HIV Patients 11/15/2012
Boehringer Ingelheim Corporation Release: Recruitment Complete for Trajenta ® (linagliptin) Cardiovascular Outcome Study in Patients With Type 2 Diabetes 11/8/2012
Boehringer Ingelheim Corporation Release: RELY-ABLE®: Unprecedented Long-Term Data Support Safety Profile and Sustained Efficacy of Pradaxa® for Stroke Prevention in AF 11/8/2012
Boehringer Ingelheim Corporation Release: Safety and Efficacy of Pradaxa® (dabigatran etexilate) Reconfirmed in Clinical Setting for VTE Prevention After Total Knee or Hip Replacement 11/6/2012
Novartis AG (NVS) Drug Works to Treat Rare Cushing's Disease 11/6/2012
Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation 11/5/2012
GlaxoSmithKline (GSK), Roche (RHHBY) Drugs Help Treat Breast Cancer in Brain 11/2/2012
Wealth of Worldwide Evidence on Boehringer Ingelheim GmbH's Pradaxa® Including First Clinical Data on Long-Term Efficacy and Safety of a Novel Oral Anticoagulant to be Presented at American Heart Association Scientific Sessions 10/31/2012
Novartis AG (NVS) Cannibalizes Gleevec to Boost New Cancer Drug 10/29/2012
Sleep Tight: GlaxoSmithKline (GSK) Vaccine Not Linked To Narcolepsy 10/19/2012
Eisai Company, Ltd. (ESALY.PK)'s Epilepsy Drug Helps Obese Patients Lose Weight 10/17/2012
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Makes Progress With MS Drugs 10/15/2012
Novartis AG (NVS)'s Gilenya Cuts Early Relapse, Brain Loss in MS Patients 10/12/2012
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People With Relapsing Forms of MS 10/11/2012
Sanofi (France) (SAN.PA) Says Zaltrap Cancer Drug Study Positive 10/9/2012
Sanofi (France) (SAN.PA) Flags Positive Study on Lantus Insulin 10/5/2012
Cancer Trials Show One Year on Roche (RHHBY)'s Herceptin is Best 10/1/2012
Celgene (CELG)'s Abraxane is Talk of Cancer Meeting 10/1/2012
New Janssen Pharmaceutica N.V. Data Demonstrate STELARA® (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients With Moderate to Severe Plaque Psoriasis 9/28/2012
Boehringer Ingelheim GmbH Release: Asian Populations With Atrial Fibrillation (AF) Benefit From Better Stroke Prevention With Pradaxa® (dabigatran etexilate) Compared to Warfarin 9/12/2012
New Data Confirms Safety of Novartis AG (NVS)'s Eye Drug Lucentis 9/5/2012
Novartis AG (NVS) Smoker's Cough Treatment Beats GlaxoSmithKline (GSK)'s Advair in Trial 8/29/2012
Bayer AG (BAY.F) Says Blood Thinner Cuts Risk of Repeat Heart Attack 8/29/2012
The Medicines Company (MDCO) Release: Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin 8/28/2012
AstraZeneca PLC (AZN) Release: New European Society of Cardiology Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients With ST-Elevation 8/28/2012
Daiichi Sankyo, Inc. (4568.t), Eli Lilly and Company (LLY) Say Heart Drug Effient Fails to Meet Goal in a Phase III Trial 8/27/2012
Boehringer Ingelheim Corporation Release: Cost Effectiveness and Clinical Efficacy of Pradaxa® (Dabigatran Etexilate) Versus Rivaroxaban Analysed 8/24/2012
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin 8/13/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study 8/13/2012
Roche (RHHBY) Says Avastin Slows Brain Cancer Tumor Growth 8/10/2012
Bristol-Myers Squibb Company (BMY) & AstraZeneca PLC (AZN) Release: Pooled Analysis Showed Onglyza® (saxagliptin) Provided Improvements in Key Measures of Blood Sugar Control in Adults With Type 2 Diabetes at High Risk for CV Disease 7/30/2012
Roche (RHHBY)'s Lucentis Works to Treat Vision Loss from Diabetes 7/25/2012
AstraZeneca PLC (AZN) Starts New Study of Heart Drug Versus Rival 7/18/2012
GlaxoSmithKline (GSK), Shionogi & Co., Ltd. Say HIV Drug Beats Gilead Sciences, Inc. (GILD) Atripla in Test 7/11/2012
Merck KGaA (MKGAF.PK) Says Erbitux Fails in Stomach Cancer Trial 7/6/2012
Orexo AB Takes Large Step Forward on the Road to Improve Treatment for People Dependent on Opioid Pain Killers 7/2/2012
Boehringer Ingelheim Corporation Release: No Significant Difference in the Risk of Acute Coronary Syndrome (including Myocardial Infarction) Seen With Pradaxa®(dabigatran etexilate) Compared to Enoxaparin for VTE Prevention After Orthopaedic Surgery 6/25/2012
Genentech (RHHBY) Says Perjeta Combination Increased Survival in Breast Cancer Patients 6/22/2012
FDA Staff Question Value of Sanofi (France) (SAN.PA) Blood Clot Drug 6/18/2012
Sanofi (France) (SAN.PA) Announces Results of ORIGIN, the World's Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes 6/15/2012
GlaxoSmithKline (GSK)'s Avandia and University of Nottingham's Actos are Linked to Vision Problems 6/13/2012
New Epidemiological Data Provide Additional Safety Evidence for Sanofi (France) (SAN.PA)'s Lantus(R) 6/12/2012
Alkermes plc (ALKS) Release: INVEGA® SUSTENNA® Three-Month Formulation of Paliperidone Palmitate Enters Phase 3 Clinical Program for Schizophrenia 6/12/2012
Sanofi (France) (SAN.PA)'s Lantus Shows No Cancer, Heart Risks: Study 6/12/2012
Novo Nordisk A/S (NVO) Says Victoza Superior to Amylin Pharmaceuticals, Inc. (AMLN) Rival 6/12/2012
Sanofi (France) (SAN.PA)'s Lantus Cut Blood Sugar More Than Merck & Co., Inc. (MRK)'s Januvia 6/11/2012
Data From Follow-Up Study of Vertex Pharmaceuticals Incorporated (VRTX)' KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People With Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D) 6/8/2012
Roche (RHHBY)'s Actemra Beats Abbott Laboratories (ABT) Drug in RA Trial 6/7/2012
European Medicines Evaluation Agency Confirms Boehringer Ingelheim Corporation's Pradaxa Benefits, But Wants Clearer Guidance 5/25/2012
Roche (RHHBY)'s Genentech (RHHBY) to Take Part in First-ever Alzheimer's Prevention Trial 5/21/2012
Merck KGaA (MKGAF.PK)'s Erbitux Fails in Colon Cancer Study 5/9/2012
Roche (RHHBY)'s Avastin and Novartis AG (NVS)'s Lucentis Equal for Treating Wet AMD - National Institutes of Health (NIH) Study 5/2/2012
New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) (BIIB) & Biogen Idec, Inc. (Massachusetts) (BIIB) Commitment to Improving Outcomes in Multiple Sclerosis 4/27/2012
Johnson & Johnson (JNJ) Alzheimer's Med Cut Chemical Tied to Brain Tangles 4/3/2012
Servier's Protelos Effective Against Weak Bones 3/26/2012
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Complete Registrational Program for Relovair; Reports Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD 3/23/2012
OncoGenex Pharmaceuticals Inc. Doubles Down on Prostate Cancer, as Competition Heats Up 3/12/2012
Novartis AG (NVS) Cancer Drugs Fight Deadly Ebola Virus in Lab, Researchers Find 3/2/2012
Roche (RHHBY)'s Zelboraf May Double Survival for Some Melanoma Patients 2/24/2012
FDA Grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma to Can-Fite BioPharma 2/23/2012
European Medicines Evaluation Agency Recommends Lifting Suspension of Bayer HealthCare (BAY)'s Trasylol 2/21/2012
AB Science (AB.PA) Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as Compared to Pfizer Inc. (PFE)'s Sutent®in Gleevec®-resistant GIST 2/1/2012
Alkermes plc (ALKS) Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence 1/31/2012
Allos Therapeutics, Inc. (ALTH) Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at theEuropean Medicines Evaluation Agency 1/30/2012
Roche (RHHBY)'s Avastin Fights Early Breast Cancer in 2 Studies: Will it be Re-approved? 1/27/2012
GlaxoSmithKline (GSK)'s Dutasteride May Slow Low-Risk Prostate Cancer: Debate Heats Up 1/24/2012
Roche (RHHBY) Melanoma Drug Spurs Growth of Other Skin Cancers: Study 1/20/2012
Sapheon, Inc. Announces One Year First-In-Man Data; Enrollment Commences in European Post Market Study 1/19/2012
Teva Pharmaceutical Industries Limited (TEVA) Release: Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE® 1/3/2012
Roche (RHHBY)'s Avastin Disappoints Against Ovarian Cancer 1/3/2012
Study Challenges Bristol-Myers Squibb Company (BMY) on Bristol-Myers Squibb Company (BMY) and Sanofi (France) (SAN.PA)'s Plavix 12/29/2011
EarlySense Release: Studies Show that EarlySense’s Contact-Free Patient Monitoring System Effectively Helps Hospital Patients Avoid Pressure Ulcers 12/19/2011
Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide 12/19/2011
Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline (GSK) Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus 12/15/2011
Celgene International Sárl (CELG) Release: Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia 12/14/2011
Celgene International Sárl (CELG) Release: Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype 12/14/2011
Celgene International Sárl (CELG) Release: Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Presented at American Society of Hematology 12/14/2011
Two Novartis AG (NVS) Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 12/13/2011
Celgene International Sárl (CELG) Release: Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA® and REVLIMID® in Higher-Risk MDS Patients Presented at American Society of Hematology 12/13/2011
Celgene International Sárl (CELG) Release: REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia 12/13/2011
Celgene International Sárl (CELG) Release: Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia 12/12/2011
Celgene International Sárl (CELG) Release: Results from a Comparative Analysis Shows REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care 12/12/2011
Roche (RHHBY) Absorbs New Setback for Avastin as Cancer Treatment 12/12/2011
Latest Data on Novartis AG (NVS) Afinitor Confirms Efficacy 12/9/2011
GlaxoSmithKline (GSK) Drug Fails to Hit Goal in Breast Cancer Trial 12/9/2011
Boehringer Ingelheim Corporation,Eli Lilly and Company (LLY) Release: Linagliptin Demonstrates Meaningful Improvement in Glycaemic Control in Initial Combination Therapy with Metformin 12/8/2011
Pooled Analysis: Fewer Major Adverse Cardiovascular Events in People with Type 2 Diabetes Treated with Merck Sharp & Dohme (MRK)'s JANUVIA ® (sitagliptin) 12/6/2011
Novo Nordisk A/S (NVO) Release: Data Show That the Combination of Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia in Type 1 and Type 2 Diabetes Patients 12/6/2011
Regeneron Pharmaceuticals, Inc. (REGN)-Bayer HealthCare (BAY) Drug Matches Lucentis at 2 Years in Fewer Doses 12/6/2011
Midatech Group Receives Regulatory Approval for Clinically Testing Ultra-small Gold Nanoparticles 11/15/2011
Sanofi (France) (SASY.PA)'s Multaq Doubled Deaths from Heart Disease in Study 11/15/2011
The Medicines Company (MDCO) Release: German Researchers Reaffirm Utility of Angiomax(R)/Angiox(R) (Bivalirudin) in High Risk PCI Patients 11/14/2011
Alkermes plc (ALKS) Release: New Long-Term Data on VIVITROL® Showed Sustained Efficacy and Safety over 18 Months of Treatment 11/9/2011